26 results
8-K
EX-99.1
BHVN
Biohaven Ltd.
9 May 24
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
4:14pm
for the potential treatment of dilated cardiomyopathy and galactose deficient IgA for IgA nephropathy."
Dr. Coric continued, “The Biohaven R&D team continues … development plans and research efforts. We look forward to unveiling further updates across our clinical programs and future development plans at our annual R&D Day
8-K
EX-99.1
BHVN
Biohaven Ltd.
15 Apr 24
Regulation FD Disclosure
6:59am
updates planned at the Company’s R&D Day on May 29, 2024 STATUS: 16 Subjects Completed Two Dosing Cohorts to Date Sentinel dosing paradigm: 1 sentinel
8-K
EX-99.1
BHVN
Biohaven Ltd.
29 Feb 24
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
4:16pm
million of restricted cash.
Fourth Quarter 2023 Financial Highlights:
Research and Development (R&D) Expenses: R&D expenses, including non-cash share … became a standalone public company.
R&D Expenses: R&D expenses, including non-cash share-based compensation, were $373.3 million for the year ended
8-K
EX-99.1
fx8w3zz61q5 gxoro
14 Nov 23
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
4:26pm
8-K
EX-99.1
6y2w6ybj8 qwj1xoh1
31 Jul 23
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
4:29pm
8-K
EX-99.1
o8llkaz2h 3cic
31 May 23
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
7:03am
8-K
5r4qlmt f1f
31 May 23
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
7:03am
8-K
EX-99.1
s7td9 wq9kzoedc6vp
12 May 23
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
4:47pm
10-Q
j3vmxxbg5m
9 Nov 22
Quarterly report
4:19pm
8-K
EX-99.1
2xul27ds56rzxe2
9 Nov 22
Biohaven LTD. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments
4:05pm
424B4
ip1m5samcjj0qvl
24 Oct 22
Prospectus supplement with pricing info
9:38am
S-1/A
sde1e30l7z k16pp9sg
20 Oct 22
IPO registration (amended)
10:00am
S-1
6w39 har3mdzjp07lj
18 Oct 22
IPO registration
4:03pm
DRS
2xhewu8
11 Oct 22
Draft registration statement
12:00am